EP1644032A1 - Inhibiteurs de la migration cellulaire - Google Patents

Inhibiteurs de la migration cellulaire

Info

Publication number
EP1644032A1
EP1644032A1 EP04742119A EP04742119A EP1644032A1 EP 1644032 A1 EP1644032 A1 EP 1644032A1 EP 04742119 A EP04742119 A EP 04742119A EP 04742119 A EP04742119 A EP 04742119A EP 1644032 A1 EP1644032 A1 EP 1644032A1
Authority
EP
European Patent Office
Prior art keywords
prommp
cells
mmp
integrin
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04742119A
Other languages
German (de)
English (en)
Inventor
Michael Stefanidakis
Erkki Koivunen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CTT Cancer Targeting Technologies Oy
Original Assignee
CTT Cancer Targeting Technologies Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20030923A external-priority patent/FI20030923A/fi
Priority claimed from FI20040616A external-priority patent/FI20040616A0/fi
Application filed by CTT Cancer Targeting Technologies Oy filed Critical CTT Cancer Targeting Technologies Oy
Publication of EP1644032A1 publication Critical patent/EP1644032A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18

Definitions

  • the present invention concerns peptide compounds, which bind to the OC M integrin I- domain and inhibit its complex formation with proMMP-9, thereby preventing neutrophil migration.
  • the compounds can be used in treatment of inflammatory conditions.
  • Polymorphonuclear neutrophils constitute the majority of the blood leukocytes and play a pivotal role in acute inflammation by phagocytosing and killing invading microorganisms.
  • the neutrophils contain four granule compartments: azurophilic granules, specific granules, gelatinase granules, and secretory vesicles, defined by their high content of myeloperoxidase (MPO), lactoferrin (LF), gelatinase, and latent alkaline phosphatase, respectively.
  • MPO myeloperoxidase
  • LF lactoferrin
  • gelatinase and latent alkaline phosphatase, respectively.
  • Proteolytic enzymes including elastase (1), collagenase (2), and MMP-9 are located in these granules and are important for leukocyte exit from the bone marrow into the circulation and recruitment into the inflammatory sites (3).
  • MMP-9 plays a role in tissue remodeling, tissue repair and wound healing, and is a marker of inflammatory diseases such as rheumatoid arthritis (4) and multiple sclerosis (5).
  • PMNs produce MMP-9 during the late stages of maturation in the bone marrow where it is stored in its latent form (proMMP-9) within the gelatinase granules.
  • proMMP-9 zymogen is induced and secreted in response to extracellular stimuli, which initiate specific signalling cascades such as the protein kinase C pathway (6, 7).
  • MMP-9 is also released from human leukocytes after pre-treatment of cells with soluble agonists, such as the complement anaphylatoxin C5a (8) and the tumor necrosis factor- ⁇ (TNF- ⁇ ) (9).
  • soluble agonists such as the complement anaphylatoxin C5a (8) and the tumor necrosis factor- ⁇ (TNF- ⁇ ) (9).
  • TNF- ⁇ tumor necrosis factor- ⁇
  • MMP-9 expression is induced as a result of (X M P 2 integrin ligation in PMNs (10) and (X L P 2 integrin ligation in T lymphoma cells (12).
  • proMMP-9 As a result, three different forms of proMMP-9 are released to the extracellular space as detected by zymography: a 92kDa monomer, a 200 kDa homodimer, and a 120 kDa complex of MMP-9 bound to neutrophil gelatinase-associated lipocalin (NGAL), a 25 IcDa member of the lipocalin family of transport proteins.
  • Activation of proMMP-9 can be achieved extracellularly by proteinases, or chemically by mercurial compounds or reactive oxygen species (13, 14). Once activated, secreted MMP-9 can be inhibited by the tissue inhibitor of metalloproteinases (TIMP) and ⁇ 2 -macroglobulin present in the extracellular space.
  • TIMP tissue inhibitor of metalloproteinases
  • TIMP only weakly inhibits the surface MMP-9 of neutrophils (15). Thus, the cell surface localization constitutes yet another level for MMP activity regulation.
  • IMMs intracellular adhesion molecules 1-5
  • the leukocyte integrins need activation to become fully functional (17).
  • T lymphocytes have been most thoroughly studied and activation can occur through the T cell receptor (17, 19) and may involve protein kinase C (20).
  • X M P 2 is known to be located intracellularly in specific granules and upon activation it is translocated to the cell surface (21). Not much is known about the mechanism of translocation and which cellular components are involved.
  • proMMP-9 we have mapped the major integrin recognition sequence of proMMP-9 to be present in the MMP catalytic domain (16). That sequence was mimicked by phage display peptides discovered by biopanning on the integrin (XM I domain, the most active peptide being ADGACILWMDDGWCGAAG (DDGW).
  • XM I domain the most active peptide being ADGACILWMDDGWCGAAG (DDGW).
  • DDGW ADGACILWMDDGWCGAAG
  • a peptide as small as six amino acids in length derived from the MMP-9 catalytic domain was capable of competing with proMMP-9 binding to the ⁇ 2 integrin.
  • the hexapeptide and DDGW both attenuated PMN migration in vitro and in vivo, suggesting a role for the MMP-integrin complex in PMN motility.
  • proMMP-9/ ⁇ M ⁇ 2 complex is important for neutrophil motility but we cannot exclude the possibility that the peptides also affect other ⁇ 2 integrin ligands than proMMP-9.
  • DDGW and HFDDDE inhibited the transwell and transendothelial migration of activated neutrophils but not that of resting cells indicates specificity for the action of the peptides.
  • proMMP-9 is a component of the ⁇ 2 integrin-directed neutrophil migration at least under these in vitro conditions.
  • proMMP-9 promatrix metalloproteinases, particularly proMMP- 9, are potent ligands of the leukocyte ⁇ 2 integrins.
  • proMMP-9 the major MMP and integrin of neutrophils.
  • the proMMP-9/ ⁇ .M ⁇ 2 complex was primarily detected in intracellular granules, but after cellular activation it became localized to the cell surface as demonstrated by immunoprecipitation and double immunofluorescence.
  • proMMP-9 is known to localize to the same intracellular granules as the ay$ 2 integrin
  • association of proMMP-9 with ciMp2 intracellularly has not been shown before. That proMMP-9 is directly able to bind to the (X M integrin I domain suggests that the interaction between endogenous proMMP-9 and ⁇ M ⁇ 2 is direct although we cannot exclude the possibility of accessory molecules.
  • ⁇ M ⁇ 2 may have a specific carrier function for some proteinases.
  • ICAM-I or fibrinogen do not compete with proMMP-9 binding and the DDGW peptide inhibitor of the proMMP-9/a]v$2 complex is unable to inhibit leukocyte primary adhesion to ICAM-I, fibrinogen or LLG-C4-GST but still inhibits the cell migration.
  • the leukocyte ⁇ 2 integrins are involved in leukocyte mobility. Studies with CX M or OI L knockout mice also show the importance of ⁇ 2 integrins in mediating leukocyte adhesive, migratory, and phagocytic activities in response to inflammatory stimuli.
  • Leukocytes from patients with the leukocyte adhesion deficiency syndrome type I (LAD-I) have a defective ⁇ 2 integrin subunit and cannot migrate properly although they express proMMP-9, indicating that proMMP-9 alone does not confer cell migration ability.
  • LAD-I cells expressed MMP-9 immunoreactivity at the leading edge, but did not adhere to the immobilized proMMP-9.
  • proMMP-9 would associate with both the intracellular "inactive" integrin and the extracellular integrin once activated by PMA, C5a or TNF ⁇ stimulus. It remains to be determined how (pro)MMP-9 is located at the cell surface in LAD-I cells in the absence of ⁇ 2 integrin. There are a number of other binding proteins reported for MMP-9 in the literature.
  • the cell migration assays revealed two modes of cell motility: ⁇ 2 integrin-dependent that was inhibited by DDGW and other peptides, and ⁇ 2 integrin-independent that was not inhibited by the peptides.
  • ⁇ 2 integrin-dependent that was inhibited by DDGW and other peptides
  • ⁇ 2 integrin-independent that was not inhibited by the peptides.
  • the ⁇ 2 integrin- and MMP-independent leukocyte migration may correspond to the observed amoeboid-like movement of leukocytes in 3 -dimensional collagen under in vitro conditions, which is insensitive to MMP inhibitors.
  • MMP-9 null mice still show neutrophil migration in thioglycolate-induced peritonitis and in vitro transmigration of neutrophils across TNF- ⁇ -treated endothelial cells.
  • MMPs are known to have overlapping functions and other MMPs could compensate for the loss of MMP-9.
  • proMMP-2 complexes with ⁇ M ⁇ 2 and the studies here show that neutrophil MMP-8 can also bind to purified I domain.
  • HFDDDE sequence is highly conserved in secreted MMPs and such peptides from many MMPs can bind CX M I domain in a pepspot membrane assay (16, FI 20030923). It remains to be seen which MMP-integrin complexes are functional in the MMP-9 knockout mice. Furthermore, the ability of otMp2 to bind also other proteinases such as elastase and urokinase likely affects neutrophil invasivity.
  • DDGW and HFDDDE had potent activities in vivo in the mouse peritonitis model, but it is unclear to what extent this was due to inhibition of proMMP-9 as both peptides can potentially inhibit other ⁇ 2 integrin ligands as well.
  • a subset of ⁇ 2 integrin ligands have a DDGW-like sequence and these include, in addition to MMPs, at least complement iC3b and thrombospondin-1.
  • Our results suggest that the proMMP-9/oiM ⁇ 2 complex may be part of the neutrophil's machinery for a specific ⁇ 2 integrin-directed movement.
  • the present invention is thus directed to new peptide compounds, in specific to a peptide compound comprising the hexapeptide motif HFDDDE.
  • Said compounds can be used as pharmaceuticals, which inhibit neutrophil migration.
  • the inhibitory activity was shown both in in vitro and in vivo experiments. Consequently, the compounds can be used to prevent and treat inflammatory conditions.
  • the invention thus concerns a compound comprising the hexapeptide motif HFDDDE, and, especially, such a compound for use in inhibiting neutrophil migration, and such a compound for use in prevention and treatment of inflammatory conditions.
  • the invention is also directed to the compounds of the invention for the manufacture of a pharmaceutical composition for the treatment of conditions dependent on neutrophil migration.
  • Another embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising as an active ingredient a compound of the invention, and a pharmaceutically acceptable carrier.
  • a further embodiment of the invention is a method for therapeutic or prophylactic treatment of conditions dependent on neutrophil migration, comprising administering to a mammal in need of such treatment a neutrophil migration inhibiting compound of the invention in an amount which is effective in inhibiting migration of neutrophils.
  • Specific embodiments of the invention include methods for prophylaxis and treatment of inflammatory conditions.
  • HMEC human microvascular endothelial cell
  • PMN polymorpho- nuclear neutrophil
  • CTT CTTHWGFTLC peptide
  • CTT W ⁇ A CTTHAGFTLC peptide
  • LLG-C4 CPCFLLGCC peptide
  • DDGW ADGACILWMDDGWCGAAG peptide
  • HSA human serum albumin
  • KKGW ADGACILWMKKGWCGAAG peptide
  • LF lactoferrin
  • MPO myeloperoxidase
  • NGAL neutrophil gelatinase-associated lipocalin
  • GPA glycol- phorin A
  • TAT-2 tumor-associated trypsinogen-2.
  • FIGURE IA to IE Double immunofluorescence staining for av$ 2 and proMMP-9 in human neutrophils and LAD-I cells.
  • Freshly isolated PMNs (IA, IB, 1C, and ID) from healthy donors and LAD-I cells (IE) were double stained for MMP-9 and ⁇ M p 2 integrin (see Experimental). Briefly, unstimulated (IA and IB) or PMA-stimulated PMNs (1C and ID) were added to poly-L-lysine-coated coverslips, fixed, and permeabilized (IA and 1C) or not (IB and ID).
  • Non-permeabilized LAD-I cells were fixed and stained similarly. Fluorescence was detected by confocal microscopy (A, B, C, D, and E; bars: 4.5, 3.4, 7.0, 4.8, and 5.8 ⁇ m, respectively). The experiments were repeated at least 3 times with similar results.
  • FIGURE 2A to 2F Subcellular fractionation of nitrogen-cavitated disrupted neutrophils on a Percoll gradient. Isolated neutrophils were kept on a resting state or stimulated prior to cell lysis. After Percoll gradient centrifugation, fractions were divided into the populations denoted ⁇ , ⁇ l, ⁇ 2, and ⁇ , respectively. SO, supernatant before or after PMA- stimulation; Sl, postnuclear supernatant; S2, cytosolic material. These pooled fractions were assayed for MPO (2A), NGAL (2B), LF (2C), MMP-9 (2D), HSA (2E), and HLA (2F) by ELISA. The experiment was repeated at least 3 times with similar results.
  • FIGURE 3A to 3D Subcellular localization of (XMP 2 and MMP-9 in neutrophils granules.
  • THP-I cells were pulse labeled with [ 35 S]-methionine for 10 min followed by chase for up to 4 h.
  • Cell lysates were incubated with anti-MMP-9, anti- ⁇ M , or control (human IgG) antibodies for 3 h.
  • the immunoprecipitates were visualized by fluorography after 24 h. The positions of proMMP-9 and ⁇ X M subunit are marked.
  • FIGURE 4A to 4D (X M -I domain binding to recombinant MMP-9 domains.
  • FIGURE 5A to 5D Recognition of recombinant MMP-9 domains by ⁇ M ⁇ 2 integrin- expressing cells.
  • the studied cells were PMNs (5A, 5B, 5C), V.M$ 2 L-cell transfectants (5D), non-transfectants (5D), and LAD-I cells (5D).
  • PMNs were in resting state or stimulated with PMA (5 A, 5C) or C5a or TNF ⁇ (5B) before the binding experiment to proMMP-9 or its domains.
  • Cells were also pretreated with each peptide (50 ⁇ M), antibody (20 ⁇ g/ml) or the CX M I domain as indicated. Unbound cells were removed by washing and the number of adherent cells was quantitated by a phosphatase assay. The experiment was repeated three times with similar results.
  • FIGURE 6 A to 6D Blockage of PMN and THP-I cell migration in vitro by gelatinase and ⁇ 2 integrin inhibitors.
  • PMNs (1x10 5 in 100 ⁇ l) were applied on the LLG-C4-GST or GST coated surface (6A) or HMEC monolayer (6B) in the absence or presence of peptides (200 ⁇ M) or antibodies (20 ⁇ g/ml) as indicated.
  • PMNs were stimulated with 20 nM PMA (6A), HMECs with 50 ⁇ M C5a or 1 Ong/ml TNF ⁇ or left untreated (6B).
  • THP- 1 cells (5xlO 4 in lOO ⁇ l) were stimulated with 50 nM PMA and applied on the coated surfaces together with each peptide (200 ⁇ M) (6C). The cells migrated through transwell filters were stained and counted microscopically. All experiments were reapeated at least twice.
  • FIGURE 7A to 7D Inhibition of neutrophil migration to an inflammatory tissue.
  • mice were injected with thioglycolate or PBS intraperitoneally.
  • the peptides were applied intravenuously at the amounts indicated (A).
  • the intraperitoneal leukocytes were harvested and counted.
  • the results show means ⁇ SD of 2 - 4 mice in a group. (*) indicates statistical significant difference (p ⁇ 0.001).
  • the experiment was repeated at least 3 times.
  • the infiltrated neutrophils of mice treated with thioglycolate (7B) or PBS (7C) were stained with anti-MMP-9 and anti- ⁇ M , as described in the figure 3 legend. Fluorescence was studied by confocal microscopy. Bars: 9.1 ⁇ m and 4.8 ⁇ m, respectively.
  • PMNs were isolated from peripheral blood anticoagulated in acid-citrate dextrose. Erythrocytes were sedimented by centrifugation on 2% Dextran T-500, and the leukocyte-rich supernatant was pelleted, resuspended in saline and centrifuged on a Lymphoprep (Nyegaard, Oslo, Norway) at 40Og for 30 minutes to separate polymorphonuclear cells from platelets and mononuclear cells (22). PMN purity was >95% with typically ⁇ 2% eosinophils. Cell viability was measured using an MTT (3- [4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium) bromide assay as instructed by the manufacturer (Roche).
  • MTT 3- [4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
  • HMEC-I Human microvascular endothelial cells
  • LAD-I Leukocyte adhesion deficiency type-1
  • LAD-I Leukocyte adhesion deficiency type-1
  • ⁇ M ⁇ 2 -transfected L929 mouse fibroblastic cells were generous gifts from Dr. Jean-Pierre Cartron (INSERM, Paris, France). These cells were maintained as described previously (26) and the ci M ⁇ 2 expression was examined by fluorescence-activated cell sorting (FACS, Becton Dickinson, San Jose, CA).
  • the monoclonal antibodies MEMl 70 and OKMlO are against the integrin ⁇ X M subunit (25).
  • the monoclonal anti-MMP-9 antibody (GE-213) was obtained from Lab Vision (Fremont, CA) and polyclonal MMP-9 from Santa Cruz Biotechnology (Santa Cruz, CA). We also used the previously reported affinity purified antibodies against MMP-9 (3).
  • As monoclonal antibody controls we used a mouse IgG (Silenius, Hawthorn, Australia) and anti-glycophorin A (GPA) (ATCC).
  • Anti-trypsinogen-2 (TAT-2) antibody was a rabbit polyclonal antibody control (27).
  • the peroxidase-conjugated anti-GST mAb was from Santa Cruz Biotechnology.
  • a rat antibody against the mouse (X M integrin (MCA74) and a FITC-co ⁇ jugated anti-rat (Fab') 2 were purchased from Serotec (Oxford, UK).
  • the peptides CTT, W ⁇ A CTT, LLG-C4, DDGW, and KKGW have been described earlier (16, 28).
  • the HFDDDE and DFEDHD peptides were custom-made by Neosystem (Strasbourg, France).
  • ProMMP-8 and proMMP-9 were obtained from Calbiochem and Roche, respectively. Diisopropyl fluorophosphate was from Aldrich Chemical Company Inc. (Steinheim, Germany).
  • Human C5a and recombinant TNF- ⁇ were purchased from Calbiochem (Biosciences, Inc. La Jolla, CA) and Sigma-Aldrich (St. Louis, MO), respectively.
  • MPO ⁇ band/azurophil
  • LF ⁇ l band/specific
  • gelatinase ⁇ 2 band/gelatinase
  • albumin ⁇ band/secretory vesicles and plasma membranes
  • Gelatin zymography, immunoprecipitation, and immunoblotting Granules fractions were lysed on ice for 15 min with 1% (v/v) Triton-X-100 in phosphate buffered saline (PBS), and the lysate was clarified by centrifugation for 10 min at +4 °C.
  • the lysates were analyzed by gelatin zymography on 8% SDS-polyacrylamide gels containing 0.2 % gelatin (27). Before immunoprecipitation, the lysate was precleared by incubating for 30 min at +4 0 C with protein G-Sepharose.
  • the membrane was incubated with a monoclonal CC M (MEM 170) antibody (10 ⁇ g/ml) for 2 h at room temperature followed by horseradish peroxidase-conjugated rabbit anti- mouse IgG (l :1000-dilution; DAKO A/S, Copenhagen, Denmark) at 25°C for 30 min. After several washes, the blot was developed with the Enhanced ChemiLuminescence system (Amersham Pharmacia Biotech) according to the manufacturer's instructions. The membranes were ' stripped of bound antibodies and reprobed with a polyclonal anti-MMP- 9 antibody. An appropriate secondary antibody was used. The membranes were stored in TBS at +4 0 C after each immunodetection.
  • Non-activated or PMA-activated (50 nM) THP-I cells (1 x 10 7 ) were subjected to biosynthetic labeling using [ 35 S] -methionine (31).
  • Cells were suspended in methionine- free medium containing 10% dialyzed, heat-inactivated fetal calf serum and were pulsed- labeled with 50 ⁇ Ci/ml of [ 35 S] -methionine at +37 0 C for 10 min. The cells were rapidly washed and further incubated in a complete medium containing 10 % FCS at +37°C for indicated time points.
  • the labeling was stopped by pelleting the cells and adding 2 ml of cold PBS at 3 different time points (30 min, 2 h, and 4 h, respectively). After washings, the cells were lysed with a buffer containing 1% Triton X-100, 10 ⁇ g/ml of aprotinin, 10 ⁇ g/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride in PBS, clarified by ultracentrifugation and precleared with protein G-Sepharose. The lysate was immuno- precipitated with affinity purified rabbit anti-MMP-9 and monoclonal (X M (OKM-IO) (3 ⁇ g/ml). A human IgGj was a control antibody.
  • MMP-9 proteins (200 nM in PBS) were coated at +4°C for 16 h and the microtiter wells were blocked with 3 % BSA in PBS for 1 h at room temperature.
  • the (X M p2-integrin L- cell transfectants and PMNs (1x10 5 cells/well) were suspended in RPMI medium supplemented with 2mM MgCl 2 and 0.1% BSA and activated with PMA (2OnM) for 20 min, or with C5a (5OnM) or TNF- ⁇ (1OnM) for 4h at +37°C.
  • LAD-I cells were used as controls.
  • the cells were treated with the indicated antibody (20 ⁇ g/ml) or peptide (50 ⁇ M) at +37°C for 30 min, washed twice with serum-free medium and incubated in the microtiter wells at +37°C for 30 min.
  • the wells were washed with PBS, and the number of adherent cells was quantitated by a phosphatase assay (25).
  • HMECs 4x10 5 cells/well were grown on the upper side of the gelatin-coated membrane for 5 days. Culture medium was changed after 3 days.
  • chemotactic activation was carried out by adding C5a (5OnM), TNF- ⁇ (10ng/ml), or medium alone to the lower compartment at +37 0 C for 4 h. Cultures were then washed again twice to remove all agents. PMNs or THP-I cells were preincubated with the peptide inhibitor or antibody studied for 1 h before transfer to the upper compartment (1x10 5 cells in lOO ⁇ l RPMI/0.1 % BSA or the complete 10 % FCS-containing medium). PMNs were allowed to migrate for 2 h through the LLG-C4-GST coated membrane and for 30 min through the HMEC monolayer. THP-I cells were allowed to migrate for 16 h. The non-migrated cells were removed from the upper surface by a cotton swab and the cells that had traversed the filters were stained with crystal violet and counted.
  • mice at the age of 31-32 weeks were injected intraperitoneally with 3% (w/v) thioglycolate in sterile saline (32).
  • Peptides (5-500 ⁇ g in lOO ⁇ l) were introduced intravenously through the tail vein.
  • Animals were euthanized after 3 h and the peritoneal cells were harvested by injecting 10 ml of sterile PBS through the peritoneal wall. Red blood cells present in the lavage fluid were removed by hypotonic lysis. Cells were centrifuged and resuspended in 1 ml of sterile 0.25% BSA/Krebs-Ringer. The supernatants were also collected and analysed by gelatin zymography.
  • the number of neutrophils was determined following staining with 0.1% crystal violet and using a light microscope equipped with a x 100 objective.
  • immunofluorescence staining cells were allowed to bind to poly-L-lysine coated cover slips, fixed with 2.5% paraformaldehyde in PBS at +4°C for 30 min followed by several washings. The Fc receptors were blocked in the presence of 20% of rabbit serum and 3% BSA in PBS. The cells were then incubated with anti-MMP-9 polyclonal and (XM monoclonal (MCA74) antibodies for 30 min.
  • the secondary antibodies After washing with PBS, the secondary antibodies, rhodamine (TRITC)-conjugated anti-rabbit or FITC-conjugated anti-rat (Fab') 2 were incubated for another 30 min. The samples were examined with a confocal microscope. The animal studies were approved by an ethical committee of Helsinki University.
  • Results were analysed using the F-test (ANOVA) and subsequently, if significant differences between groups occurred, they were subjected to Duncan's Multiple Range test.
  • the program used was SPSS for Windows release 8.0.
  • THP-I cells 50 000/100 ⁇ l were incubated in serum-free RPMI for 16 h in the presence or absence of peptides (200 ⁇ M) as described in the text.
  • the supernatants from THP-I cells and mouse intraperitoneal fluid were analysed by gelatin zymography. Gelatinolytic activity was quantified by densitometric scanning.
  • proMMP-9 and oi M ⁇ 2 suggested the formation of the proMMP-9/ ⁇ M ⁇ 2 integrin complex in the PMN granules before translocation to the cell surface.
  • MPO was used as a marker for azurophil granules; LF and NGAL for specific granules; MMP-9 for gelatinase granules; human serum albumin (HSA) for secretory vesicles; and human leukocyte antigen (HLA) for plasma membranes (Fig. 2).
  • PMA induced the release of the majority of the granule markers to the extracellular milieu, whereas MPO was only partially released from azurophil granules.
  • Both NGAL and LF were discharged from the specific granules into the supernatant (SO) by 75% and 90%, respectively.
  • HSA from the secretory vesicles was discharged by 85% and detected in large amounts in SO supernatant.
  • HLA a marker of the plasma membrane, remained relatively constant.
  • the levels of HSA, NGAL, LF, and MMP-9 were substantially decreased in the postnuclear supernatants (Sl) after cell activation.
  • the cytosolic fraction (S2) was devoid of these markers, indicating that the subcellular fractionation led to the isolation of intact granules.
  • the proMMP-9 zymogen was found in the ⁇ band, representing secretory vesicles and plasma membranes, and in the extracellular milieu (SO).
  • the CI M integrin antibody OKM-IO immunoprecipitated the 165IdDa (X M -chain from the ⁇ l-, ⁇ 2-, and ⁇ -bands.
  • the 92 ItDa proMMP-9 co-precipitated from the ⁇ 2-band (Fig. 3C).
  • the CI M chain was immunoprecipitated from the ⁇ l- and ⁇ -bands but not anymore from the ⁇ 2-band.
  • the integrin antibody co-precipitated proMMP-9 only from the ⁇ -band. Addition of soluble (X M I-domain prevented the co-precipitation.
  • the biosynthesis of an endogenous complex between proMMP-9 and aiv$ 2 integrin was investigated in the THP-I leukemic cell line, which is amenable for such studies.
  • the complex was detected at 2 h and 4 h time points by immunoprecipitation from [ 35 S]- methionine pulsed cells (Fig. 3D, lanes 5 and 8).
  • the OKMlO antibody coprecipitated the
  • OI M chain was only weakly seen in the immunoprecipitates with anti-MMP-9 antibodies (lanes 4 and 7), possibly because of a large excess of unliganded proMMP-9.
  • a control antibody did not coprecipitate OCM and proMMP-9
  • Peptide inhibitors of the proMMP-9/ ⁇ Mp2 complex prevent neutrophil migration
  • pepspot analysis located the integrin interactive site of proMMP-9 to a 20-amino acid long sequence present in the catalytic domain, QGDAHFDDDELWSLGKGVVV (see the first priority document). Further screening by the pepspot system has indicated that sufficient integrin binding activity is achieved by truncating this sequence to a hexapeptide, HFDDDE (data not shown). To confirm that such a short sequence is the bioactive site of proMMP-9, we first prepared bacterially expressed recombinant domains of MMP-9 (Fig. 4A). ⁇ MMP-9 is composed of the prodomain (Pro) and the catalytic domain but lacks the hemopexin domain.
  • the fibronectin type II repeats were also produced as a separate recombinant protein as this is an important substrate-binding region.
  • the procatalytic domain construct ⁇ MMP-9 bound the CC M I domain nearly as efficiently as the wild type proMMP-9 (Fig. 4B).
  • FnII protein almost lacked activity.
  • the HFDDDE peptide identified by the solid-phase pepspot analysis was highly active when made by peptide synthesis and inhibited proMMP-9 binding to the ⁇ M I domain with an IC 50 of 20 ⁇ M (Fig. 4C).
  • the bound proMMP-9 was determined with the GE-213 antibody, which recognizes an epitope of the FnII domain (data not shown).
  • HFDDDE was equally potent as DDGW, the Ot M I domain-binding peptide discovered by phage display.
  • KKGW the control peptide for DDGW, was without effect.
  • HFDDDE sequence is highly conserved in the members of the MMP family, we also examined the (XM I domain binding to human neutrophil collagenase, MMP-8. I domain showed a similar DDGW-inhibitable binding to proMMP-8 as to proMMP-9 (Fig. 4D). ICAM-I and fibrinogen did not compete with either proMMP, implying different binding sites for the matrix proteins and proMMPs in the I domain.
  • PMNs After integrin activation, PMNs exhibited an ability to adhere on proMMP-9. PMA- stimulated PMNs bound to microtiter well-coated ⁇ MMP-9 nearly as strongly as to proMMP-9 (Fig. 5A). Stimulation of PMNs with C5a or TNF- ⁇ gave similar results PMN adherence increasing by 3-fold (Fig. 5B). The FnII domain did not support PMN adhesion. PMN adherence was inhibited by HFDDDE (50 ⁇ M), DDGW (50 ⁇ M), the soluble CI M I domain and the MEM170 antibody (Fig. 5C), indicating ⁇ 2 integrin-directed binding.
  • the control peptides (DFEDHD, KKGW) and an irrelevant monoclonal antibody (anti-GPA) had no effect.
  • the CTT peptide but not the W ⁇ A CTT control peptide lacking MMP inhibitory activity, binds to the MMP-9 catalytic domain (unpublished results) and also inhibited the PMN adherence. MMP-9 antibodies inhibited partially.
  • DDGW concentration-dependent and up to 90 % inhibition was obtained by doses of 50 ⁇ g and 500 ⁇ g per mouse, respectively.
  • DDGW was active even at 5 ⁇ g given per mouse corresponding to an effective dose of 0.1mg/kg mouse tissue.
  • PMNs were present intraperitoneally after thioglycolate-stimulus in comparison to the PBS control.
  • the collected inflammatory PMNs stained positively for the proMMP-9/ ⁇ M ⁇ 2 complex by double immunofluorescence (Fig. IB).
  • the cells collected after PBS injection lacked the complex; they expressed the integrin but had no cell-surface MMP-9 (Fig. 1C).
  • Fibronectin-mediated cell adhesion is required for induction of 92-kDa type IV collagenase/gelatinase (MMP-9) gene expression during macrophage differentiation - The signaling role of protein kinase C-beta. J. Biol. Chem. 273:11576.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne des composés peptidiques qui s'avèrent se lier au domaine de l'intégrine I aM I et qui inhibent sa formation complexe avec proMMP-9, ce qui empêche la migration des neutrophiles. Les composés comprennent le motif hexapeptidique HFDDDE et peuvent être utilisés dans la prophylaxie et le traitement des états inflammatoires.
EP04742119A 2003-06-19 2004-06-21 Inhibiteurs de la migration cellulaire Withdrawn EP1644032A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20030923A FI20030923A (fi) 2003-06-19 2003-06-19 Leukosyytti-proMMP-9/beta2-integriinikompleksin inhibiittorit
FI20040616A FI20040616A0 (fi) 2004-04-29 2004-04-29 Solumigraation inhibiittorit
PCT/FI2004/000376 WO2004110478A1 (fr) 2003-06-19 2004-06-21 Inhibiteurs de la migration cellulaire

Publications (1)

Publication Number Publication Date
EP1644032A1 true EP1644032A1 (fr) 2006-04-12

Family

ID=33553915

Family Applications (2)

Application Number Title Priority Date Filing Date
EP04742119A Withdrawn EP1644032A1 (fr) 2003-06-19 2004-06-21 Inhibiteurs de la migration cellulaire
EP04742118A Withdrawn EP1644031A1 (fr) 2003-06-19 2004-06-21 Inhibiteurs du complexe prommp-9 leucocytaire /integrine beta (2)

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP04742118A Withdrawn EP1644031A1 (fr) 2003-06-19 2004-06-21 Inhibiteurs du complexe prommp-9 leucocytaire /integrine beta (2)

Country Status (3)

Country Link
EP (2) EP1644032A1 (fr)
JP (2) JP2006527741A (fr)
WO (2) WO2004110478A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2595935A1 (fr) * 2005-01-31 2006-08-03 Fondazione Centro San Raffaele Del Monte Tabor Composition
GB2429012A (en) * 2005-08-12 2007-02-14 Cartela Ab Polypeptides capable of binding an integrin I-domain.
WO2007020405A2 (fr) * 2005-08-12 2007-02-22 Cartela R & D Ab Nouveaux peptides et utilisations associees
ES2641751T3 (es) 2008-11-04 2017-11-13 Index Pharmaceuticals Ab Compuestos y métodos para reducir el reclutamiento y/o la migración de células polimorfonucleares
US8003110B1 (en) * 2011-01-24 2011-08-23 Matthias W. Rath Metalloproteinase oligopeptides and their therapeutic use
CN110691606A (zh) 2017-03-22 2020-01-14 儿童医学中心公司 Prss2抑制
AU2018240303A1 (en) 2017-03-22 2019-10-10 Children's Medical Center Corporation LRP1 binding agents and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817750A (en) * 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
US20030022835A1 (en) * 1998-04-29 2003-01-30 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
GB9809764D0 (en) * 1998-05-07 1998-07-08 Isis Innovation MMP-9 Gene polymorphisms
CN1379685A (zh) * 1999-07-13 2002-11-13 南加利福尼亚大学 用基于MMP－9和β1整联蛋白的拮抗剂抑制血管发生的新方法和组合物
AU4347701A (en) * 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7034134B2 (en) * 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
WO2003091391A2 (fr) * 2002-04-23 2003-11-06 Duke University Genes determinants pour phenotype atheroscclerotique et methodes d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STEFANIDAKIS M ET AL: "Identification of a Negatively Charged Peptide Motif within the Catalytic Domain of Progelatinases That Mediates Binding to Luekocyte beta-2 Integrins", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 36, 5 September 2003 (2003-09-05), pages 34674 - 34684 *

Also Published As

Publication number Publication date
WO2004110478A1 (fr) 2004-12-23
EP1644031A1 (fr) 2006-04-12
JP2006527740A (ja) 2006-12-07
WO2004110477A1 (fr) 2004-12-23
JP2006527741A (ja) 2006-12-07

Similar Documents

Publication Publication Date Title
Stefanidakis et al. Intracellular and cell surface localization of a complex between αMβ2 integrin and promatrix metalloproteinase-9 progelatinase in neutrophils
Chazaud et al. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations
López‐Alemany et al. Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against α‐Enolase
Witko-Sarsat et al. Presence of Proteinase 3 in Secretory Vesicles: Evidence of a Novel, Highly Mobilizable Intracellular Pool Distinct From Azurophil Granules: Presented in part at the 17th European Workshop on the Cell Biology of Phagocytes, Catania, Italy, May 1998.
Montuori et al. The cleavage of the urokinase receptor regulates its multiple functions
Noh et al. Role of urokinase receptor in tumor progression and development
Wei et al. Regulation of integrin function by the urokinase receptor
Preissner et al. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.
Lehti et al. Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface
Syrovets et al. Novel aspects and new roles for the serine protease plasmin
Ratnikov et al. An alternative processing of integrin αv subunit in tumor cells by membrane type-1 matrix metalloproteinase
Rozanov et al. The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells
Bianchi et al. Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes.
Soehnlein et al. Neutrophils launch monocyte extravasation by release of granule proteins
Reuning et al. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins
US20070207967A1 (en) Peptide Inhibitors of Matrix Metalloproteinase Activity
Staudt et al. Processing of CXCL12 by different osteoblast-secreted cathepsins
Garwicz et al. Characterization of the processing and granular targeting of human proteinase 3 after transfection to the rat RBL or the murine 32D leukemic cell lines
WO2004110478A1 (fr) Inhibiteurs de la migration cellulaire
Deryugina et al. Prointegrin maturation follows rapid trafficking and processing of MT1‐MMP in Furin‐Negative Colon Carcinoma LoVo Cells
Taekema-Roelvink et al. Proteinase 3 interacts with a 111-kD membrane molecule of human umbilical vein endothelial cells
Mambole et al. The cleavage of neutrophil leukosialin (CD43) by cathepsin G releases its extracellular domain and triggers its intramembrane proteolysis by presenilin/γ-secretase
Kobayashi et al. Immunolocalizations of human gelatinase (type IV collagenase, MMP-9) and TIMP (tissue inhibitor of metalloproteinases) in normal epidermis and some epidermal tumors
Preissner et al. The dual role of the urokinase receptor system in pericellular proteolysis and cell adhesion: implications for cardiovascular function
Gerspach et al. Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

17Q First examination report despatched

Effective date: 20071016

18W Application withdrawn

Effective date: 20071008